New VA study finds Paxlovid may cut the risk of long COVID

with No Comments
Even patients who were vaccinated or boosted, or had repeat COVID-19 infections, had a similar reduction in the risk of developing long COVID, the study found.


(Pien Huang/ NPR) — It’s well-documented that Paxlovid — a 5-day course of antiviral pills from Pfizer — can reduce the risk of hospitalization in COVID-19 patients who are more likely to develop severe illness.

Now, researchers from the Veterans Health Administration find that taking the medication may also reduce the risks of later developing long COVID, according to a new study that was posted online this weekend and has not yet undergone peer review.

“We’ve already known for some time now that Paxlovid reduces the risk of acute problems,” says Dr. Ziyad Al-Aly, chief of research and development at the VA Saint Louis Healthcare System, and co-author of the study, “Now we are adding the observation that Paxlovid also reduces the risk of long COVID.” (…)

read full story